CareTrust REIT (NASDAQ: CTRE ) reported Q2 EPS of $0.21, in-line with the analyst estimate of $0.21. Revenue for the quarter came in at $47.56 million versus the consensus estimate of $47.4 million.

Historical data for the Manba Finance Ltd share (MNBA) as well as the closing price, open, high, low, change and %change.

Market Analysis by covering: Gold Spot US Dollar, Gold Futures. Read 's Market Analysis on Investing.com ZA.

Alvotech (NASDAQ:ALVO), a global biosimilars company, has been making waves in the pharmaceutical industry with its ambitious growth strategy and recent product launches. As the company positions ...

MP Materials Corp. (NYSE:MP), the largest rare earth materials producer in the Western Hemisphere with a market capitalization of $3.54 billion, stands at a critical juncture as it navigates a complex ...

Arthur J. Gallagher & Co. (NYSE:AJG), a global insurance brokerage and risk management services firm, has been the subject of intense scrutiny by financial analysts as it navigates a complex market ...

Celldex (NASDAQ:CLDX) Therapeutics, Inc. (NASDAQ:CLDX) is a biotechnology company focused on developing innovative treatments for mast cell-related diseases, with its lead candidate barzolvolimab ...

Global-E Online Ltd (NASDAQ:GLBE), a leading provider of cross-border e-commerce solutions with a market capitalization of $7.37 billion, has been navigating a complex market landscape characterized ...

Global Medical REIT Inc . (NYSE:GMRE), a company focused on acquiring and leasing healthcare facilities, has been navigating a challenging market environment while maintaining its strategic focus on ...

Meta Platforms, Inc. (NASDAQ:META) continues to dominate the social media landscape while making significant strides in artificial intelligence (AI) and digital advertising. With a market ...

Ares Capital Corporation stands out as a prominent specialty finance company, primarily focusing on providing debt and equity financing solutions to middle-market companies. With a track record ...

Jasper Therapeutics, Inc. (NASDAQ:JSPR), a clinical-stage biotechnology company, has been making waves in the field of mast cell-mediated diseases with its lead asset, briquilimab. As the company ...